¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Multiple Daily W/Beta Oral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® oral administration ÇÑ±Û °æ±¸º¹¿ë
¼³¸í   
  ¾àÀ» Åõ¿©Çϴ ¹æ¹ý¿¡´Â ¿©·¯ °¡Áö°¡ ÀÖ´Ù. Å©°Ô ³ª´©¾î º¸¸é, ÀÔÀ» °ÅÃÄ À§Ã¢Àڰ踦 ÅëÇØ ³Ö´Â ¹æ¹ý°ú À§Ã¢Àڰ踦 ÅëÇÏÁö ¾Ê°í ¹Ù·Î Ç÷¾×À¸·Î ³Ö´Â ¹æ¹ýÀÌ ÀÖ´Ù. À§Ã¢Àڰ踦 ÅëÇÏÁö ¾Ê´Â ¹æ¹ýÀ¸·Î °¡Àå ÈçÇÑ ¹æ¹ýÀº Áֻ縦 ÀÌ¿ëÇϴ ¹æ¹ýÀÌ´Ù. ÇÏÁö¸¸, À̿ܿ¡ Ç×¹®À» ÅëÇØ ³Ö´Â Á¾à½Ä¹æ¹ý°ú Çô¹Ø¿¡ ³Ö´Â Çô¹ØÅõ¿©¹ýµµ ÀÖ´Ù. ±×·¯³ª ´ëºÎºÐÀÇ ¾àÁ¦´Â °æ±¸º¹¿ëÀ» ÇϰԠµÈ´Ù. °æ±¸º¹¿ë¿¡ ´ëÇÑ ¾àÀڴ p.o.(per oral)·Î Ç¥±âÇÑ´Ù. °æ±¸º¹¿ëÁ¦ÀÇ ´ÜÁ¡Àº º¹¿ëÇÑ ¾àÁ¦°¡ À§Ã¢ÀÚ°ü°è¸¦ °ÅÄ¡¸é¼­ »ç¶÷¸¶´Ù °¢±â ´Ù¸¥ Èí¼öÁ¤µµ¿Í ´ë»çÁ¤µµ¸¦ °ÅÄ¡°Ô µÇ¹Ç·Î ÀÏÁ¤ÇÑ ³óµµÀ¯Áö°¡ ¾î·Æ´Ù´Âµ¥ ÀÖ´Ù. ¶ÇÇÑ °æ±¸º¹¿ëÁ¦ÀÇ ¸ð¾çÀ̠ĸ½¶ÇüÀÎÁö, È¤Àº °¡·çÇüÀÎÁö¿¡ µû¶ó¼­µµ °°Àº ¾àÀÌÁö¸¸, ¼­·Î ´Ù¸¥ È¿°ú¸¦ ³ªÅ¸³¾ ¼ö ÀÖ´Ù.
¿µ¹® oral cavity ÇÑ±Û ±¸°­
¼³¸í   
  ÀÔÀ» ¹ú¿©¼­ ÀÔ¼Ó¿¡¼­ º¼ ¼ö Àִ °ø°£À¸·Î ÀÔõÀå, Æíµµ, ¸ñÁ¥À» º¼ ¼ö ÀÖ´Ù.
  
  ±¸°­
¿µ¹® multiple sclerosis ÇÑ±Û ´Ù¹ß°æÈ­Áõ
¼³¸í   
  ½Å°æÃà»èÀ» µÑ·¯½Î°í Àִ ¸»ÀÌÁý(myelin sheath)ÀÇ ÆÄ±«·Î ÀÎÇÑ º´Àû»óŸ¦ ¸»ÇÔ. ÆÄ±«µÈ ¸»ÀÌÁýÀº ÈäÅ͸¦ ³²±â°Ô µÇ¾î ½Å°æÃà»èÀ» ÅëÇÑ ½Å°æÀü´ÞÀÌ Á¦´ë·Î µÇÁö ¾Ê¾Æ ¿îµ¿, °¨°¢, ÀÚÀ²½Å°æ ¸ðµÎÀÇ ½Å°æÀü´ÞÀå¾Ö°¡ ³ªÅ¸³­´Ù. ÀÌ º´Åʹ ¾îµð¼­³ª ³ªÅ¸³¯ ¼ö À־ ±× Àå¾Ö°¡ ³ªÅ¸³ª´Â ºÎÀ§¿¡ µû¶ó ¼­·Î ´Ù¸¥ Áõ»óÀ» È£¼ÒÇÑ´Ù.
¿µ¹® multiple myeloma ÇÑ±Û ´Ù¹ß°ñ¼öÁ¾
¼³¸í   
  ´Ù¹ß¼º ¿ø¹ß¼º°ñÁ¾¾ç. ¸Ó¸®»À-°¥ºñ»À-º¹Àå»À-ôÃß»À-°ñ¹Ý µî¿¡ Àß ³ªÅ¸³ª°í, ¹°··¹°··ÇÑ Á¾±«¸¦ Çü¼ºÇϸç, »ÀÀÇ Èí¼ö°¡ ÀϾ°í, 40~60¼¼ ³²ÀÚ¿¡°Ô ¸¹ÀÌ ¹ß»ýÇÑ´Ù. °ñ¼öÁ¾ Á¾¾ç¼¼Æ÷´Â ÇüÁú¼¼Æ÷¿¡¼­ À¯·¡ÇÑ °ÍÀ̾ ÇüÁú¼¼Æ÷Á¾À̶ó°íµµ ÇÑ´Ù. °ú°Å¿¡´Â ÇüÁú¼¼Æ÷¼º°ñ¼öÁ¾ À̿ܿ¡´Â ´Ù¸¥ °ñ¼öÁ¶Ç÷¿ä¼Ò¿¡¼­ »ý±â´Â °ñ¼öÁ¾À̶ó°í »ý°¢ÇßÁö¸¸ ÇöÀç´Â ºÎÁ¤µÇ°í ÀÖ´Ù. ÇüÁú¼¼Æ÷´Â ¿ø·¡ ¸é¿ª±Û·ÎºÒ¸°À» »ý»êÇϴ ¼¼Æ÷À̸ç, ±×°ÍÀÌ Á¾¾çÈ­ÇÑ ´Ù¹ß °ñ¼öÁ¾ È¯ÀÚ¿¡¼­µµ ´ëºÎºÐ Ç÷û ¼Ó¿¡ ¸é¿ª ±Û·ÎºÒ¸°ÀÌ Áõ°¡µÈ °ÍÀ» º¼ ¼ö ÀÖ´Ù. Áõ°¡ÇÑ ±Û·ÎºÒ¸°Àº IgG³ª IgAÀΠ°æ¿ì°¡ ¸¹Áö¸¸ ´Ù¸¥ Çüµµ ÀÖ´Ù. °ñ¼öÁ¾ È¯ÀÚ ¾à 50%´Â ¿ÀÁÜ¿¡¼­ º¥½ºÁÔ½º´Ü¹éÁúÀÌ °ËÃâµÇ´Âµ¥, ÀÌ ´Ü¹éÁúÀÇ ÃàÀû¿¡ ÀÇÇØ ¿ä¼¼°üÀÌ ÆÄ±«µÇ°í, ÄáÆÏ°æÈ­°¡ ÀϾ´Ù. °ñ¼öÁ¾ È¯ÀÚ¿¡¼­´Â Ç÷û´Ü¹é ÀÌ»óÀ¸·Î °¡²û ¾Æ¹Ð·ÎÀ̵åÁõÀÌ ³ªÅ¸³­´Ù. »À X¼± ¼Ò°ßÀ¸·Î¼­´Â µµ·Á³½ º´ÅÍ, °ñÀ¶ÇØ»ó, º´Àû°ñÀýÀÌ °üÂûµÈ´Ù.
¿µ¹® multiple personality ÇÑ±Û ´ÙÀμº ÀΰÝ
¼³¸í   
  Çظ®¼º Á¤½ÅÀå¾ÖÀÇ Çϳª·Î ³ªÅ¸³­´Ù. ÇÑ »ç¶÷ÀÌ ¿©·¯ »ç¶÷ÀÇ ¼º°ÝÀ» ¼ÒÀ¯Çϰí Àִ °ÍÀ¸·Î ¸¶Ä¡ ¡°Áöų¹Ú»ç¿Í ÇÏÀ̵堾¾¡±¿Í °°Àº °æ¿ìÀÌ´Ù. ¾Æ¸¶, ÇöÀç ÀÚ½ÅÀǠóÁö¿¡¼­ ¹þ¾î³ª°í ½ÍÀº ¹«ÀǽÄÀûÀΠ¿å¸Á¿¡¼­ ºñ·ÔµÇ´Â °ÍÀ¸·Î ¿©°ÜÁø´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acceptable daily dose
    ÀÏÀÏÇã¿ë·®
  • acceptable daily intake
    ÀÏÀϼ·ÃëÇã¿ë·®
  • daily mean
    ÇÏ·çÆò±ÕÄ¡
  • maximum acceptable daily intake
    ÀÏÀϼ·ÃëÃÖ´ëÇã¿ë·®
  • beta cell
    º£Å¸¼¼Æ÷
  • beta counting
    º£Å¸°è¼ö
  • beta emitter
    º£Å¸¹æÃâü
  • beta error
    º£Å¸¿À·ù, Á¦2Çü¿À·ù
  • beta hemolysis
    º£Å¸¿ëÇ÷, ¿ÏÀü¿ëÇ÷
  • beta particle
    º£Å¸ÀÔÀÚ
  • beta ray
    º£Å¸¼±
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼ö¿ëüÀλêÈ­È¿¼Ò
  • beta-carotene
    º£Å¸Ä«·Îƾ
  • beta-lactam
    º£Å¸¶ôŽ
  • beta-lactamase
    º£Å¸¶ô޾ÆÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta-carotene
    º£Å¸Ä«·Îƾ
  • beta cell
    º£Å¸¼¼Æ÷
  • beta hemolysis
    º£Å¸¿ëÇ÷
  • beta ray
    º£Å¸¼±
  • multiple birth
    ´Ù»ê, ´ÙÅÂÃâ»ê
  • plural multiple birth
    ´Ù»ê, ´ÙÅÂÃâ»ê
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù-
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • multiple sclerosis
    ´Ù¹ß°æÈ­Áõ
  • multiple causation theory
    Áúº´¹ß»ý´Ù¿äÀμ³
  • oral cavity
    ÀÔ¾È, ±¸°­
  • oral contraceptive
    °æ±¸ÇÇÀÓÁ¦, ¸Ô´ÂÇÇÀÓÁ¦
  • oral contraception
    °æ±¸ÇÇÀÓ
  • oral floor
    ÀԾȹٴÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acceptable daily dose
    ÀÏÀÏÇã¿ë·®
  • acceptable daily intake
    ÀÏÀϼ·ÃëÇã¿ë·®
  • daily mean
    ÀÏÆò±ÕÄ¡
  • maximum acceptable daily intake
    ÀÏÀϼ·ÃëÃÖ´ëÇã¿ë·®
  • minimal daily requirement
    ÃÖ¼Ò¿µ¾çÇʿ䷮, ÃÖ¼ÒÀÏÀϿ䱸·®
  • beta cell
    º£Å¸¼¼Æ÷
  • beta counting
    º£Å¸°è¼ö
  • beta emitter
    º£Å¸¹æÃâ±â
  • beta error
    Á¦ÀÌÁ¾¿À·ù
  • beta hemolysis
    º£Å¸¿ëÇ÷, ¿ÏÀü¿ëÇ÷
  • beta particle
    º£Å¸ÀÔÀÚ
  • beta ray
    º£Å¸¼±
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼º¼ö¿ëüÀλêÈ­È¿¼Ò
  • oral administration
    °æ±¸Åõ¿©
  • oral angle
    ÀÔ²¿¸®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Daily activities
    ÀÏ»óȰµ¿
  • acceptable daily dose : ADD
    ÀÏÀÏÇã¿ë·®(ìéìíúÉé»Õá).
  • acceptable daily intake =ADI
    ÀÏÀϼ·ÃëÇã¿ë·®(ìéìíàîö¢úÉé»åÖ).
  • instrumental activites of daily living
    ÁÖ°£»ýȰ ±â±âȰµ¿
  • 11-beta-hydroxylase
    11-º£Å¸-¼ö»êÈ­È¿¼Ò, 11-º£Å¸-È÷µå·Ï½Ç¶óÁ¦
  • 3-beta-hydroxysteroid dehydrogenase
    3-º£Å¸-È÷µå·Ï½Ã½ºÅ×·ÎÀ̵å Å»¼ö¼ÒÈ¿¼Ò
  • Cowdens syndrome = multiple hamartoma syndrome
    ´Ù¹ß¼º °ú¿ÀÁ¾ ÁõÈıº
  • MOTSA (multiple overlapping thin-slab acquisition)
    ´ÙÁß Áߺ¹ ¼¼ÆíÆÇ ȹµæ
  • O-Nitrophenyl-beta-galactoside => ONPG
    O-´ÏÆ®·ÎÆä´Ò-º£Å¸-°¥¶ôÅä½Ãµå
  • acetyl-beta-methylcholine
    ¾Æ¼¼Æ¿-º£Å¸-¸ÞÆ¿Äݸ°
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • arch, oral
    ±¸°³±Ã, ÀÔ±Ã
  • gamma-delta-beta thalassemia
    °¨¸¶-µ¨Å¸-º£Å¸- ÁöÁßÇØ¼ººóÇ÷
  • gland(s), oral
    ±¸°­¼±
  • hemorrhage, oral
    ±¸°­ÃâÇ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta-ARK : beta-adrenergic receptor kinase
    º£Å¸-¾Æµå·¹³¯¸°(¼º)¼ö¿ëü ÀλêÈ­È¿¼Ò.
  • acceptable daily dose : ADD
    ÀÏÀÏÇã¿ë·®(ìéìíúÉé»Õá).
  • acceptable daily intake =ADI
    ÀÏÀϼ·ÃëÇã¿ë·®(ìéìíàîö¢úÉé»åÖ).
  • daily mean
    ÀÏ(ÀÏ)Æò±ÕÄ¡
  • diurnal variation =daily v.
    Àϳ»º¯µ¿(ìíҮܨÔÑ).
  • instrumental activites of daily living
    ÁÖ°£»ýȰ ±â±âȰµ¿
  • maximum acceptable daily intake =MADI
    ÀÏÀϼ·ÃëÃÖ´ëÇã¿ë·®(ìéìíàîö¢õÌÓÞúÉé»åÖ).
  • maximum acceptable daily intake =MADI
    ÀÏÀϼ·ÃëÃÖ´ëÇã¿ë·®(ËöËöËÛ̧̬ËÀÌ´ËíËâ).
  • minimal daily requirement
    ÃÖ¼Ò¿µ¾çÇʿ䷮(õÌá³ç½å×ù±é©åÖ), ÃÖ¼ÒÀÏÀϿ䱸·® .
  • minimal daily requirement
    ÃÖ¼Ò¿µ¾çÇʿ䷮(õÌá³ç½å×ù±é©åÖ), ÃÖ¼ÒÀÏÀÏ
  • minimum daily requirement
    ÃÖ¼ÒÀÏÀÏÇʿ䷮.
  • acetyl-beta-methylcholine
    ¾Æ¼¼Æ¿-º£Å¸-¸ÞÆ¿Äݸ°
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • beta (¥â) chain
    º£Å¸»ç½½, º£Å¸¼â
  • beta (¥â) globulin
    º£Å¸±Û·ÎºÒ¸°
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Beta cell [Insulin cell]
    º£Å¸¼¼Æ÷ [Àν´¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] º£Å¸¼¼Æ÷
  • Multiple placenta
    ¹µÅ¹Ý
    [¿¾ ¿ë¾î] ´Ù¹ß¼ºÅ¹Ý
  • Multiple deformity
    º¹ÇÕ±âÇü
    [¿¾ ¿ë¾î] ´Ù¹ß¼º±âÇü
  • Multiple morphologic defect
    º¹ÇÕÇüŰáÇÔ
    [¿¾ ¿ë¾î] ´Ù¹ß¼ºÇüÅÂÇÐÀû°áÇÔ
  • Oral cavity proper
    °íÀ¯ÀÔ¾È
    [¿¾ ¿ë¾î] °íÀ¯±¸°­
  • Oral orifice
    ÀÔ±¸¸Û
    [¿¾ ¿ë¾î] ±¸°ø
  • Oral angle
    ÀÔ²¿¸®
    [¿¾ ¿ë¾î] ±¸°¢
  • Oral region
    ÀÔºÎÀ§
    [¿¾ ¿ë¾î] ±¸ºÎ
  • ORAL CAVITY
    ÀÔ¾È [±¸°­]
    [¿¾ ¿ë¾î] ±¸°­
  • Oral part of pharynx
    ÀÔÀεÎ
    [¿¾ ¿ë¾î] ±¸ÀεÎ
  • Oral mucosa
    ÀÔÁ¡¸·
    [¿¾ ¿ë¾î] ±¸°­Á¡¸·
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multiple budding
    ´Ù¼öÃâ¾Æ
  • multiple fission
    ´ÙºÐ¿­
  • oral infection
    °æ±¸°¨¿°
  • oral stylet
    ±¸ºÎħ
  • oral sucker
    ±¸Èí¹Ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multiple alleles
    º¹´ë¸³À¯ÀüÀÚ(ÜÜÓߨ¡ë¶îîí­)
  • multiple binding
    ´ÙÁß°áÇÕ(ÒýñëÌ¿ùê)
  • multiple codon recognition
    ´Ù(Òý)ÄÚµ· ÀÎÁö(ìãò±)
  • multiple displacement mechanism
    ´Ù(Òý)´ëü(ÓÛôð) ±âÀü(Ѧï®)
  • multiple factor hypothesis
    ´ÙÀÎÀÚ¼³(Òýì×í­àã)
  • multiple gene
    ´ÙÀ¯ÀüÀÚ(Òýë¶îîí­)
  • multiple inhibition analysis
    ´ÙÁß(Òýñì)ÀúÇØ ºÐ¼®(îÁúªÝÂà°)
  • beta
    "º£Å¸, (ÔÒ) ¥â"
  • beta adrenergic blocker
    º£Å¸ ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
  • beta amylase
    º£Å¸ ¾Æ¹Ð·¹À̽º
  • beta bend
    º£Å¸ ±ÁÀ½
  • beta benzyme
    º£Å¸ º¥ÀÚÀÓ
  • beta blocker
    º£Å¸ Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta carotene
    º£Å¸ Ä«·ÎÅÙ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • daily work
    Àϰú
  • beta
    º£Å¸
  • beta blocker
    º£Å¸Â÷´ÜÁ¦
  • oral
    ÀÔÀÇ, °æ±¸ÀÇ, ±¸°­ÀÇ
  • oral administration
    °æ±¸Åõ¿©, ³»º¹
  • oral cavity
    ±¸°­
  • oral cholecystography
    °æ±¸´ã³¶Á¶¿µ¼ú
  • oral contraceptive
    °æ±¸¿ëÇÇÀÓÁ¦
  • oral deformity
    ±¸°­º¯Çü
  • oral hygiene
    ±¸°­À§»ý
  • oral intake
    °æ±¸(Àû)¼·Ãë
  • oral mucosa
    ±¸°­Á¡¸·
  • oral surgery
    ±¸°­¿Ü°ú(ÇÐ)
  • MOTSA [=multiple overlapping thin-slab acquisition]
    ´ÙÁßÁߺ¹¼¼ÆíÆÇȹµæ
  • multiple
    ´Ù¹ß¼º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
ORS olfactory reference syndrome; oral rehydration solution; oral surgery, oral surgeon; Orthopaedic Res...
ADD acceptable daily dose; adduction; adenosine deaminase; attentional deficit disorder; average daily d...
ADI Academy of Dentistry International; acceptable daily intake; AIDS-defining illness; allowable daily ...
DRF Daily Rating Form; daily replacement factor; Deafness Research Foundation; dose reduction factor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MDI multiple daily injection
[(123)I]-beta-CIT 123)I]-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane
3 beta-diol alpha-Androstane-3 beta,17 beta-diol
ADI Acceptable Daily Intake
ADL Activities of Daily Life
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • beta-aminoisobutyric aciduria ¿äÁß¿¡ º£Å¸-¾Æ¹Ì³ë ¾ÆÀ̼ҴлêÀÌ °úµµ·Î ¹è¼³µÇ´Â °Í. ¾ç¼ºÀÇ À¯Àü¼º ´ë»ç¼º ÀÌ»óÀ¸·Î ÀϾ¸ç ±×¸®°í ƯÁ¤ÇÑ Áúȯ¿¡¼­µµ ³ªÅ¸³­´Ù.

    beta-arrestin

    º£Å¸-¾î·¹½ºÆ¾
  • multiple fission,multiple division
    ´Ù ºÐ¿­
    1°³ÀÇ ¸ð¼¼Æ÷°¡ ÀϽÃÀûÀ¸·Î ´Ù¼öÀÇ µþ ¼¼Æ÷·Î ³ª´©¾îÁö´Â ÀÏ. º¹ ºÐ¿­À̶ó°íµµ ÇÑ´Ù. ¸ðü°¡ 2°³ÀÇ µþ °³Ã¼·Î ³ª´©¾îÁö´Â 2ºÐ¿­¿¡ ´ëÇÏ¿© ÀϽÿ¡ ´Ù¼öÀÇ µþ °³Ã¼·Î ºÐ¿­ÇÏ´Â Çö»óÀ» ¸»ÇÑ´Ù. ¿ø»ýµ¿¹° Æ÷ÀÚÃæ·ùÀÇ Áõ¿ø»ý½Ä µî¿¡¼­ º¼ ¼ö ÀÖ´Ù. Áï, ÇÙ¸¸ÀÌ ºÐ¿­À» µÇÇ®ÀÌÇÏ¿© ´ÙÇÙü°¡ µÈ µÚ¿¡ ¼¼Æ÷ÁúÀÌ ÀÏÁ¦È÷ ºÐ¿­ÇÏ¿© °¢°¢ ÇÙ 1°³¾¿À» ÇÔÀ¯ÇÏ´Â µþ °³Ã¼·Î ³ª´©¾îÁø´Ù.
  • acceptable daily intake
    ÀÏÀÏ ¼·Ãë Çã¿ë·®
  • daily dose
    ÀÏÀÏ·®, ÀϿ뷮
  • daily metabolism
    ÀÏÀÏ ¹°Áú ´ë»ç
  • daily secretion rate
    ÀÏÀÏ ºÐºñ·®
  • ordinary daily responsibility
    ÀÏ»óÀûÀÎ ¸ÅÀÏÀÇ Ã¥ÀÓÀ¸·ÎºÎÅÍ ¸éÁ¦
  • A beta
    A º£Å¸, A º£Å¸ ½Å°æ ¼¶À¯
    Á¢ÃË, ¾Ð·Â, Áøµ¿ µî ´ëºÎºÐÀÇ Ã˰¢À» Àü´ÞÇÏ´Â ±½Àº À¯¼ö ½Å°æÀÌ´Ù. Á÷°æÀº 13-22§­, ½Å°æ Àü´Þ ¼Óµµ´Â 70-120§½ÀÌ´Ù.
  • A-beta fiber
    A-º£Å¸ ½Å°æ ¼¶À¯
    Á¢ÃË, ¾Ð·Â ÀÚ±ØÀ» Àü´ÞÇÏ´Â À¯¼ö ½Å°æÀÌ´Ù.
  • acetyl-beta-methylcholine
    ¾Æ¼¼Æ¿-º£Å¸-¸ÞÆ¿Äݸ°
  • beta
    ¥â
    hemolysis
  • beta
    º£Å¸
    ±×¸®½º¾î ¾ËÆÄºªÀÇ µÎ ¹øÂ° ¹®Àڷμ­ È­ÇÐ¸í¿¡ À־´Â 2°³ ÀÌ»óÀÇ À̼ºÃ¼ Áß Çϳª¸¦ Ç¥½ÃÇÏ´Â µ¥ »ç¿ëÇÑ´Ù. ¶ÇÇÑ È­ÇÕ¹°¿¡¼­ ġȯ ¿øÀÚ³ª ¿øÀÚ´ÜÀÇ À§Ä¡¸¦ Ç¥½ÃÇÏ´Â µ¥ »ç¿ëµÈ´Ù.
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
  • beta hemolysis
    º£Å¸ ¿ëÇ÷, º£Å¸Çü ¿ëÇ÷
  • beta ray
    º£Å¸ ¼±
    ¹æ»ç¼± ¹°Áú¿¡¼­ ³ª¿À´Â ÀüÀÚ¼±À¸·Î ±¤¼ÓÀÇ 0.98¹èÀÇ ÃÖ´ë¼Óµµ¸¦ °¡Áø´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
acceptable daily intake <pharmacology> This is an estimate of the amount of a substance in food that can be ingested daily over a lifetime by humans without appreciable health risk.
The concept of the acceptable daily intake has been developed principally by who and FAO and is relevant to chemicals such as additives to foods, residues of pesticides and veterinary drugs in foods.
Acceptable daily intakes are derived from laboratory toxicity data, and from human experiences of such chemicals when this is available, and incorporate a safety factor. The acceptable daily intake is thus an estimate of the amount of a substance in food that can be ingested over a lifetime by humans without significant risk to health (for contaminants in food and drinking water, tolerable intakes - daily or weekly - are used).
See: tolerable daily intake.
(15 Jan 1998)
activities of daily living The things we normally do in daily living including any daily activity we perform for self-care (such as feeding ourselves, bathing, dressing, grooming), work, homemaking, and leisure. The ability or inability to perform ADLs can be used as a very practical measure of ability/disability in many disorders.
(12 Dec 1998)
activities of daily living scale A scale to score physical activity and its limitations, based on answers to simple questions about mobility, self-care, grooming, etc; widely used in geriatrics, rheumatology, etc.
(05 Mar 2000)
daily dose The total amount of a remedy that is to be taken within 24 hours.
(05 Mar 2000)
tolerable daily intake TDIs are applied to chemical contaminants in food and drinking water. The presence of contaminants is unwanted and they have no useful function, differing from additives and residues where there is or was deliberate use resulting in their presence. TDIs are calculated on the basis of laboratory toxicity data with the application of uncertainty factors. A TDI is therefore an estimate of the amount of a substance (contaminant) in food or drinking water that can be ingested daily over a lifetime without a significant health risk.
(09 Oct 1997)
androst-5-ene-3 beta,17 beta-diol <chemical> An adrenal-derived oestrogenic metabolite of dhea. Evidence exist for its use as an endocrine regulator of immune response.
Pharmacological action: anabolic steroids.
Chemical name: Androst-5-ene-3,17-diol, (3beta,17beta)-
(12 Dec 1998)
beta-1,3-galactosyl-0-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase <enzyme> Capable of adding a glcnac residue to g1cnacman(3)g1cnac; from mung bean seedlings
Registry number: EC 2.4.1.146
Synonym: n-acetylglucosaminyltransferase II, gal3-(glcnac6)galnac-mucin (glcnac--gal)3-glcnactransferase
(26 Jun 1999)
beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-acetylglucosaminyl transferase <enzyme> With EC 2.4.1.148 this is called beta6-glcnac-transferase b
Registry number: EC 2.4.1.102
Synonym: gal3-galnac-mucin-6-glcnac transferase, udp-glcnac-gal1-3galnac-r-(glcnac to galnac)-beta1-6glcnac transferase, core 2 glcnac transferase, core 2-n-acetylglucosaminyltransferase, core 2 beta6-gn-t
(26 Jun 1999)
beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase <enzyme> Induced in preneoplastic stage of liver carcinogenesis promoted by orotic acid in rats; adds "bisecting n-acetylglucosaminyl residue in beta 1,4 linkage to the beta-linked mannose of the core of asparagine-linked oligosaccharides
Registry number: EC 2.4.1.144
Synonym: n-acetylglucosaminyltransferase III, udpgnac-glycopeptide beta4-n-acetylglucosaminyl transferase III, udpgnac-magtransferase III, udp-n-acetylglucosamine-beta-d-mannoside beta-1,4-n-acetylglucosaminyltransferase III
(26 Jun 1999)
beta-hydroxy-beta-methylglutaryl-CoA -OOCCH2C(OH)(CH3)CH2COS-CoA;a key intermediate in the synthesis of ketone bodies and of steroids.
Synonym: 3-hydroxy-3-methylglutaryl-CoA.
Beta-hydroxy-beta-methylglutaryl-lyase, an enzyme, found primarily in liver and rumen epithelium that catalyses the formation of acetyl-CoA and acetoacetate from beta-hydroxy-beta-methylglutaryl-CoA; a key step in ketogenesis; a deficiency of this enzyme leads to episodes of severe metabolic acidosis without ketosis.
Beta-hydroxy-beta-methylglutaryl-reductase, an enzyme that catalyses the rate-limiting step of cholesterol biosynthesis, beta-hydroxy-beta-methylglutaryl-CoA + 2NADPH + 2H+ &rarr; mevalonate + 2NADP+ + coenzyme A.
Beta-hydroxy-beta-methylglutaryl-synthase, an enzyme in mitochondria that catalyses the reaction of acetyl-CoA with acetoacetyl-CoA and water to form beta-hydroxy-beta-methylglutaryl-CoA and coenzyme A, a step required for both ketogenesis and steroidogenesis to occur.
(05 Mar 2000)
beta-n-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase <enzyme> An enzyme that catalyses the transfer of galactose from udp-galactose to a specific glycoprotein receptor, 2-acetamido-2-deoxy-d-glucosyl-glycopeptide, during glycopeptide synthesis.
Chemical name: UDPgalactose:N-acetyl-beta-D-glucosaminylglycopeptide beta-1,4-galactosyltransferase
Registry number: EC 2.4.1.38
(12 Dec 1998)
beta, or beta-value <radiobiology> Ratio of plasma kinetic pressure to magnetic-field pressure, proportional to the ratio of plasma kinetic energy density to magnetic field energy density. Beta is usually measured relative to the total, local field (loosely called beta toroidal), but sometimes the plasma pressure relative to only the poloidal component of the field (beta poloidal) or relative to some external field (like the maximum field at the magnetic coils) is more useful. There is also a normalised beta (beta_N) of interest when discussing the beta limit. (lots of help from Art Carlson with the above.) Because the cost of a reactor is strongly influenced by the strength of the magnetic field that must be provided, beta values are directly related to the economics of fusion power production. Beta is usually expressed as a percentage, with 5% generally believed to be the minimum value required for an economical fusion reactor.
See: pressure, kinetic pressure, magnetic pressure, second stability.
(09 Oct 1997)
UDP-GalNAc-beta-galactose beta 1,4-N-acetylgalactosaminyltransferase <enzyme> Consider also EC 2.4.1.92
Registry number: EC 2.4.1.-
Synonym: beta-1,4-n-acetylgalactosaminyltransferase, 4-galnactransferase, udp-n-acetylgalactosamine-beta-galactose beta 1,4-n-acetylgalactosaminyltransferase, (1-4)-n-acetyl-beta-d-galactosaminyltransferase, galnact-1
(26 Jun 1999)
5 alpha-androstane-3 beta,17 beta-diol 6 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostatic microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 6 alpha-hydroxylase
(26 Jun 1999)
5 alpha-androstane 3 beta,17 beta-diol 7 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostate microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 7 alpha-hydroxylase
(26 Jun 1999)
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 1 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oral
    ±¸µÎ(±¸¼ú)ÀÇ;~ly ad
  • oral approach
    (¿Ü±¹¾îÀÇ) ±¸µÎ µµÀÔ ±³¼ö¹ý
  • common multiple
    °ø¹è¼ö
  • multiple
    º¹ÇÕÀÇ;´Ù¾çÇÑ;¹è¼öÀÇ;¹è¼ö;¹è¼ö·®(least common multiple ÃÖ¼Ò °ø¹è¼ö)
  • multiple choice test
    ¼±´ÙÇü Å×½ºÆ®
  • multiple cropping
    ´Ù¸ðÀÛ
  • multiple farming
    ´Ù°¢ ³ó¾÷
  • multiple shop
    ¿¬¼âÁ¡
  • beta
    º£Å¸
  • Phi Beta Kappa
    ÆÄÀÌ.º£Å¸.Ä«ÆÄŬ·´
  • beta
    º£Å¸(±×¸®½º¾î ¾ËÆÄºªÀÇ µÑ° ÀÚ)
  • beta minus
    2·ùÀÇÇÏ;2·ùº¸´Ù Á» ¸øÇÑ
  • beta particle
    º£Å¸ÀÔÀÚ
  • beta rays
    º£Å¸¼±
  • beta rhythm
    º£Å¸¸®µë(¸ÅÃÊ 10ÀÌ»óÀÇ ³úÆÄÀÇ ¹éµ¿)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á